Pharmaceutical Resources Announces Marketing Rights to Famotidine (Pepcid(R))

Apr 16, 2001, 01:00 ET from Pharmaceutical Resources, Inc.

    SPRING VALLEY, N.Y., April 16 /PRNewswire/ -- Par Pharmaceutical, Inc.,
 ("Par"), a wholly owned subsidiary of Pharmaceutical Resources, Inc. ("PRI")
 (NYSE:   PRX; PSE), will market famotidine developed by Dr. Reddy's Laboratories
 ("Reddy").  Marketing of the 20mg and 40mg tablets will begin immediately.
     The drug was developed by Reddy and will be marketed by Par in the United
 States.  Reddy received final approval from the FDA today.
     Famotidine is the generic version of Merck's Pepcid(R).  Sales of
 Pepcid(R) in the past twelve months have been approximately $450 million.
 Famotidine is indicated for the short-term treatment of active duodenal ulcer.
     Reddy is a pharmaceutical development and bulk chemical manufacturer.  The
 company develops bulk chemical actives and final dosage form products, and is
 one of India's largest pharmaceutical companies.
     PRI is a holding company that develops, manufactures, and distributes
 generic pharmaceutical products through Par.  For press release and other
 Company information, visit our website at http://www.parpharm.com.
 
     Certain statements in this press release constitute  "forward-looking
 statements" within the meaning of the Private Securities Litigation Reform Act
 of 1995, including those concerning management's expectations with respect to
 future events or future financial performance. Any such statements that refer
 to PRI's anticipated future results, product performance, or other
 non-historical facts are forward-looking and reflect PRI's current perspective
 of existing trends and information.  These statements involve risks and
 uncertainties that cannot be predicted or quantified and consequently, actual
 results may differ materially from those expressed or implied by such
 forward-looking statements.  Such risks and uncertainties include, among
 others, the timeliness with which regulatory authorizations and product
 introductions may be achieved, market acceptance of PRI's products, the
 availability of raw materials on commercially reasonable terms, successful
 compliance with extensive, costly, complex, and evolving governmental
 regulations and restrictions, exposure to product liability, and other risks
 and uncertainties detailed in PRI's filings with the Securities and Exchange
 Commission, such as the Company's Form 10-K, Form 10-Q, and Form 8-K reports.
 
 

SOURCE Pharmaceutical Resources, Inc.
    SPRING VALLEY, N.Y., April 16 /PRNewswire/ -- Par Pharmaceutical, Inc.,
 ("Par"), a wholly owned subsidiary of Pharmaceutical Resources, Inc. ("PRI")
 (NYSE:   PRX; PSE), will market famotidine developed by Dr. Reddy's Laboratories
 ("Reddy").  Marketing of the 20mg and 40mg tablets will begin immediately.
     The drug was developed by Reddy and will be marketed by Par in the United
 States.  Reddy received final approval from the FDA today.
     Famotidine is the generic version of Merck's Pepcid(R).  Sales of
 Pepcid(R) in the past twelve months have been approximately $450 million.
 Famotidine is indicated for the short-term treatment of active duodenal ulcer.
     Reddy is a pharmaceutical development and bulk chemical manufacturer.  The
 company develops bulk chemical actives and final dosage form products, and is
 one of India's largest pharmaceutical companies.
     PRI is a holding company that develops, manufactures, and distributes
 generic pharmaceutical products through Par.  For press release and other
 Company information, visit our website at http://www.parpharm.com.
 
     Certain statements in this press release constitute  "forward-looking
 statements" within the meaning of the Private Securities Litigation Reform Act
 of 1995, including those concerning management's expectations with respect to
 future events or future financial performance. Any such statements that refer
 to PRI's anticipated future results, product performance, or other
 non-historical facts are forward-looking and reflect PRI's current perspective
 of existing trends and information.  These statements involve risks and
 uncertainties that cannot be predicted or quantified and consequently, actual
 results may differ materially from those expressed or implied by such
 forward-looking statements.  Such risks and uncertainties include, among
 others, the timeliness with which regulatory authorizations and product
 introductions may be achieved, market acceptance of PRI's products, the
 availability of raw materials on commercially reasonable terms, successful
 compliance with extensive, costly, complex, and evolving governmental
 regulations and restrictions, exposure to product liability, and other risks
 and uncertainties detailed in PRI's filings with the Securities and Exchange
 Commission, such as the Company's Form 10-K, Form 10-Q, and Form 8-K reports.
 
 SOURCE  Pharmaceutical Resources, Inc.